company background image
VISTN logo

Vistin Pharma OB:VISTN Stock Report

Last Price

NOK 24.40

Market Cap

NOK 1.1b

7D

2.5%

1Y

5.2%

Updated

22 Dec, 2024

Data

Company Financials

Vistin Pharma ASA

OB:VISTN Stock Report

Market Cap: NOK 1.1b

VISTN Stock Overview

Through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. More details

VISTN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends3/6

Rewards

Trading at 75% below our estimate of its fair value

Earnings grew by 37.9% over the past year

Risk Analysis

Does not have a meaningful market cap (NOK1B)

Unstable dividend track record


My Notes

Capture your thoughts, links and company narrative

Vistin Pharma ASA Competitors

Photocure

OB:PHO

NOK 1.7b

Navamedic

OB:NAVA

NOK 457.5m

ArcticZymes Technologies

OB:AZT

NOK 687.4m

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E

CASE:RMDA

ج.م5.1b

Price History & Performance

Summary of share price highs, lows and changes for Vistin Pharma
Historical stock prices
Current Share PriceNOK 24.40
52 Week HighNOK 28.80
52 Week LowNOK 20.70
Beta0.90
1 Month Change-0.41%
3 Month Change-12.23%
1 Year Change5.17%
3 Year Change36.47%
5 Year Change130.19%
Change since IPO29.10%

Recent News & Updates

Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Sep 18
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Recent updates

Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Sep 18
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

Feb 23
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Sep 09
A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Aug 25
Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

Mar 15
Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Feb 20
We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

Jan 29
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Jan 08
The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Dec 16
Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Nov 26
Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Shareholder Returns

VISTNNO PharmaceuticalsNO Market
7D2.5%-7.3%-2.8%
1Y5.2%-3.3%-0.8%

Return vs Industry: VISTN exceeded the Norwegian Pharmaceuticals industry which returned -3.3% over the past year.

Return vs Market: VISTN exceeded the Norwegian Market which returned -0.8% over the past year.

Price Volatility

Is VISTN's price volatile compared to industry and market?
VISTN volatility
VISTN Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement5.0%
10% most volatile stocks in NO Market10.9%
10% least volatile stocks in NO Market2.6%

Stable Share Price: VISTN has not had significant price volatility in the past 3 months compared to the Norwegian market.

Volatility Over Time: VISTN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196975Magnus Tolleshaugwww.vistin.com

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.

Vistin Pharma ASA Fundamentals Summary

How do Vistin Pharma's earnings and revenue compare to its market cap?
VISTN fundamental statistics
Market capNOK 1.08b
Earnings (TTM)NOK 61.37m
Revenue (TTM)NOK 426.52m

17.6x

P/E Ratio

2.5x

P/S Ratio

Is VISTN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VISTN income statement (TTM)
RevenueNOK 426.52m
Cost of RevenueNOK 148.95m
Gross ProfitNOK 277.57m
Other ExpensesNOK 216.20m
EarningsNOK 61.37m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)1.38
Gross Margin65.08%
Net Profit Margin14.39%
Debt/Equity Ratio1.8%

How did VISTN perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

72%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mikkel Nyholt-SmedsengCarnegie Investment Bank AB